Everolimus in Patients with Autosomal Dominant Polycystic Kidney Disease
Open accessThe DOI matches its Crossref record; 21 of the 21 references it cites were found in a registry or an index.
Abstract
BACKGROUND: Autosomal dominant polycystic kidney disease (ADPKD) is a slowly progressive hereditary disorder that usually leads to end-stage renal disease. Although the underlying gene mutations were identified several years ago, efficacious therapy to curtail cyst growth and prevent renal failure is not available. Experimental and observational studies suggest that the mammalian target of rapamycin (mTOR) pathway plays a critical role in cyst growth. METHODS: In this 2-year, double-blind trial, we randomly assigned 433 patients with ADPKD to receive either placebo or the mTOR inhibitor everolimus. The primary outcome was the change in total kidney volume, as measured on magnetic resonance imaging, at 12 and 24 months. RESULTS: Total kidney volume increased between baseline and 1 year by 102 ml in the everolimus group, versus 157 ml in the placebo group (P=0.02) and between baseline and 2 years by 230 ml and 301 ml, respectively (P=0.06). Cyst volume increased by 76 ml in the everolimus group and 98 ml in the placebo group after 1 year (P=0.27) and by 181 ml and 215 ml, respectively, after 2 years (P=0.28). Parenchymal volume increased by 26 ml in the everolimus group and 62 ml in the placebo group after 1 year (P=0.003) and by 56 ml and 93 ml, respectively, after 2 years (P=0.11). The mean decrement in the estimated glomerular filtration rate after 24 months was 8.9 ml per minute per 1.73 m2 of body-surface area in the everolimus group versus 7.7 ml per minute in the placebo group (P=0.15). Drug-specific adverse events were more common in the everolimus group; the rate of infection was similar in the two groups. CONCLUSIONS: Within the 2-year study period,as compared with placebo, everolimus slowed the increase in total kidney volume of patients with ADPKD but did not slow the progression of renal impairment [corrected]. (Funded by Novartis; EudraCT number, 2006-001485-16; ClinicalTrials.gov number, NCT00414440.)
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“In addition, many agents that protect against PKD, such as rapamycin and the mTOR-independent agents carbamazepine and minoxidil can also restore autophagy in animal models177-182”
From Autophagy in kidney homeostasis and disease (2020) · cites this paper as [181]
Citations
Cites
Levey, A. S., Coresh, J., Greene, T., Stevens, L. A., Zhang, Y. (., Hendriksen, S., Kusek, J. W., & Van Lente, F. (2006) · Annals of Internal Medicine · doi:10.7326/0003-4819-145-4-200608150-00004 · Cited by 5,725
Autosomal dominant polycystic kidney disease
Torres, V. E., Harris, P. C., & Pirson, Y. (2007) · The Lancet · doi:10.1016/s0140-6736(07)60601-1 · Cited by 1,550
The Primary Cilium as the Cell's Antenna: Signaling at a Sensory Organelle
Singla, V., & Reiter, J. F. (2006) · Science · doi:10.1126/science.1124534 · Cited by 1,189
Missing Data in Clinical Studies
Molenberghs, G., & Kenward, M. G. (2007) · Wiley eBooks · doi:10.1002/9780470510445 · Cited by 962
Wilson, P. D. (2004) · New England Journal of Medicine · doi:10.1056/nejmra022161 · Cited by 916
Shillingford, J. M., Murcia, N. S., Larson, C. H., Low, S. H., Hedgepeth, R., Brown, N., Flask, C. A., Novick, A. C., Goldfarb, D. A., Kramer-Zucker, A., et al. (2006) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0509694103 · Cited by 808
Self-citationVolume Progression in Polycystic Kidney Disease
Grantham, J. J., Torres, V. E., Chapman, A. B., Guay-Woodford, L. M., Bae, K. T., King, B. F., Wetzel, L. H., Baumgarten, D. A., Kenney, P. J., Harris, P. C., et al. (2006) · New England Journal of Medicine · doi:10.1056/nejmoa054341 · Cited by 807
Autosomal Dominant Polycystic Kidney Disease
Grantham, J. J. (2008) · New England Journal of Medicine · doi:10.1056/nejmcp0804458 · Cited by 543
Chapman, A. B., Guay-Woodford, L. M., Grantham, J. J., Torres, V. E., Bae, K. T., Baumgarten, D. A., Kenney, P. J., King, B. F., Glockner, J. F., Wetzel, L. H., et al. (2003) · Kidney International · doi:10.1046/j.1523-1755.2003.00185.x · Cited by 413
Levey, A. S., Coresh, J., Greene, T., Stevens, L. A., Zhang, Y., & Hendriksen, S. M. (2008) · Annals of Internal Medicine · Cited by 394
Cited by
Tolvaptan in Patients with Autosomal Dominant Polycystic Kidney Disease
Torres, V. E., Chapman, A. B., Devuyst, O., Gansevoort, R. T., Grantham, J. J., Higashihara, E., Perrone, R. D., Krasa, H. B., Ouyang, J., & Czerwiec, F. S. (2012) · New England Journal of Medicine · doi:10.1056/nejmoa1205511 · Cited by 1,614
Global kidney health 2017 and beyond: a roadmap for closing gaps in care, research, and policy
Levin, A., Tonelli, M., Bonventre, J., Coresh, J., Donner, J.-A., Fogo, A. B., Fox, C. S., Gansevoort, R. T., Heerspink, H. J. L., Jardine, M., et al. (2017) · The Lancet · doi:10.1016/s0140-6736(17)30788-2 · Cited by 919
Self-citationHenske, E. P., Jóźwiak, S., Kingswood, J. C., Sampson, J. R., & Thiele, E. A. (2016) · Nature Reviews Disease Primers · doi:10.1038/nrdp.2016.35 · Cited by 831
Bergmann, C., Guay-Woodford, L. M., Harris, P. C., Horie, S., Peters, D. J. M., & Torres, V. E. (2018) · Nature Reviews Disease Primers · doi:10.1038/s41572-018-0047-y · Cited by 807
Ciliopathies: an expanding disease spectrum
Waters, A. M., & Beales, P. L. (2011) · Pediatric Nephrology · doi:10.1007/s00467-010-1731-7 · Cited by 676
Metadata
- Authors
- Walz, G., Budde, K., Mannaa, M., Nürnberger, J., Wanner, C., Sommerer, C., Kunzendorf, U., Banas, B., Hörl, W. H., Obermüller, N., Arns, W., Pavenstädt, H., Gaedeke, J., Büchert, M., May, C., Gschaidmeier, H., Kramer, S., & Eckardt, K.-U.
- Affiliations
- University Medical Center Freiburg (DE)
- Charité – Universitätsmedizin Berlin (DE)
- University of Duisburg-Essen (DE)
- Universitätsklinikum Würzburg (DE)
- University Hospital Heidelberg (DE)
- University Hospital Schleswig-Holstein (DE)
- University Hospital Regensburg (DE)
- Medical University of Vienna (AT)
- University Hospital Frankfurt (DE)
- Lungenklinik Köln-Merheim (DE)
- University Hospital Münster (DE)
- Novartis (Germany) (DE)
- Universitätsklinikum Erlangen (DE)
- ORCID
- Venue
- New England Journal of Medicine
- Publisher
- Massachusetts Medical Society
- Published
- 2010-08-26
- Volume
- 363
- Issue
- 9
- Pages
- 830-840
- ISSN
- 0028-4793 (ISSN-L)
- 1533-4406
- OpenAlex
- W2082060108
- Cited by
- 587
- References
- 21
- Citations by year
- 2026: 15 · 2025: 18 · 2024: 14 · 2023: 26 · 2022: 32 · 2021: 20 · 2020: 34 · 2019: 37 · 2018: 40 · 2017: 40 · 2016: 47 · 2015: 54 · 2014: 53 · 2013: 49 · 2012: 44
- FWCI
- 28.03
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Locations
- New England Journal of Medicine (publishedVersion)
- PubMed (publishedVersion)
- University of Regensburg Publication Server (University of Regensburg) (acceptedVersion)
- Universitätsbibliographie, Universität Duisburg-Essen (submittedVersion)
- Topics
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Genetics › Genetic and Kidney Cyst Diseases
- Health Sciences › Medicine › Genetics (clinical) › Tuberous Sclerosis Complex Research
- Health Sciences › Medicine › Pulmonary and Respiratory Medicine › Cystic Fibrosis Research Advances
- Keywords
- autosomal dominant polycystic kidney disease, everolimus, mTOR inhibitors, kidney cyst growth, total kidney volume, glomerular filtration rate decline, renal fibrosis, end-stage renal disease prevention, infection risk
- MeSH terms
- Everolimus, Adult, Cholesterol, Creatinine, Double-Blind Method, Female, Glomerular Filtration Rate, Humans, Kidney, Kidney Failure, Chronic, Male, Organ Size, Polycystic Kidney, Autosomal Dominant, Protein Serine-Threonine Kinases, Disease Progression, Sirolimus, Intracellular Signaling Peptides and Proteins, Young Adult, TOR Serine-Threonine Kinases
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.